World Glaucoma Day 2008: uniting to make a difference

Article

The lack of public knowledge about glaucoma surprises me. Although pretty much everybody has heard of it, little is generally known other than the fact that it affects the eye.

Still today we are hearing glaucoma specialists calling upon the medical community to educate their patients and the public about the dangers of glaucoma. Glaucoma-induced blindness is unnecessary and it is largely the lack of knowledge about the disease and the lack of obvious symptoms, which have earned it its title as the "silent blinding disease" or the "sneak thief of sight". In fact, according to a study by Sommer & co-workers in the early 90s, the silent nature of the disease, particularly in the early stages, means that up to 50% of sufferers are unaware that they have glaucoma. This figure could actually reach an astounding 90% in underdeveloped countries.

Taking these factors into account, there is little wonder that glaucoma remains the second leading cause of blindness worldwide, even though ophthalmologists do have good therapies and surgical interventions at their disposal to prevent this needless blindness.

The Ophthalmology Times group has been fortunate enough to be named the official publication of this important event and I am honoured to play a part, albeit a small one, in this commendable initiative. Please look out for coverage of these key activities both on our website ( http://www.oteurope.com/), within our weekly newsletters and in upcoming issues of our magazine. I do hope that you will join me in wishing the co-ordinators of World Glaucoma Day good luck in their efforts to reduce the unnecessary blindness caused by this condition.

Best wishes,

Fedra PavlouEditor

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.